Please login to the form below

Not currently logged in
Email:
Password:

RDX5791

This page shows the latest RDX5791 news and features for those working in and with pharma, biotech and healthcare.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    RDX5791 is an orally administered inhibitor of NHE3, a protein essential in the absorption of sodium in the intestines. ... 572. Ardelyx / AstraZeneca. Licence. RDX5791 for end stage renal and chronic kidney disease and IBS-C (phase II).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics